ArticleBlood advances2020
Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents.
Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 51 citations in OpenAlex.
- Construction and Validation of a Progression-Free Survival Prediction Model for Newly Diagnosed Multiple Myeloma Patients With 1q21 Gain/Amplification.Cancer medicine · 2026Article
- Dynamic cytogenetic evolution in multiple myeloma: prognostic implications from diagnosis to first relapse.The oncologist · 2026Article
- Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell Transplant.Transplantation and cellular therapy · 2025Article
- Poor prognosis of newly diagnosed multiple myeloma patients with 1p32.3 deletion in single monoallelic deletion and/or in main clone.British journal of haematology · 2025Article
- Article
- Chromosome 1 Alterations in Multiple Myeloma: Considerations for Precision Therapy.European journal of haematology · 2025Review
- Dissecting the high-risk property of 1q gain/amplification in patients with newly diagnosed multiple myeloma.American journal of cancer research · 2025Article
- Do Alarmins Have a Role in Multiple Myeloma?Turkish journal of haematology : official journal of Turkish Society of Haematology · 2024Article
- Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation.British journal of haematology · 2024Article
- [Application of the Second Revision of the International Staging System (R2-ISS) in the prognostic assessment of newly diagnosed multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- Chromosome-1 abnormalities in Childhood B-Lymphoblastic Leukemia - An analysis with reference to clinical variables and survival outcome.Pakistan journal of medical sciences · 2024Article
- Recent Advances in The Definition of the Molecular Alterations Occurring in Multiple Myeloma.Mediterranean journal of hematology and infectious diseases · 2024Review
- A real-world data analysis of predictors of early mortality after a diagnosis of multiple myeloma.Cancer · 2023Article
- Article
- Spatiotemporal assessment of immunogenomic heterogeneity in multiple myeloma.Blood advances · 2023Article
- Treatment Strategies for Multiple Myeloma Treatment and the Role of High-Throughput Screening for Precision Cancer Therapy.Advances in experimental medicine and biology · 2023Article
- High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions.Blood cancer journal · 2022Review
- Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup.Life (Basel, Switzerland) · 2022Review
- Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis.Blood cancer journal · 2022Observational
- The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies.Biomarker research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
Chromosome 1 abnormalities (C1As) are common genetic aberrations among patients with multiple myeloma (MM). We aimed to evaluate the significance of C1As among a contemporary cohort of patients with MM in the United States. We used electronic health records from the Flatiron Health database to select patients newly diagnosed with MM from January 2011 to March 2018 who were tested using fluorescence in situ hybridization within 90 days of diagnosis. We characterized patients as having documented C1As or other high-risk chromosomal abnormalities (HRCAs) as defined by the Revised-International Staging System (R-ISS) such as del(17p), t(14;16), and t(4;14). We used Kaplan-Meier methods to compare overall survival (OS) of patients with or without C1As and stratified log-rank tests (with the presence of HRCAs as a stratifying variable). We used Cox proportional hazards regression models to compare OS, adjusting for age, sex, stage, HRCAs, and type of first-line therapy. Of 3578 eligible patients, 844 (24%) had documented C1As. Compared with patients without C1As, patients with C1As were more likely to have higher stage (R-ISS stage III; 18% vs 12%), to have HRCAs (27% vs 14%), and to receive combinations of proteasome inhibitors and immunomodulatory agents (41% vs 34%). Median OS was lower for patients with C1As (46.6 vs 70.1 months; log-rank P < .001). C1As were independently associated with worse OS (adjusted hazard ratio, 1.42; 95% confidence interval, 1.19-2.69; P < .001), as were older age, higher R-ISS stage, HRCAs, and immunoglobulin A isotype. C1As were associated with inferior OS, independent of other HRCAs, despite greater use of novel therapies. Clinical trials testing newer therapies for high-risk MM should incorporate patients with C1As.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.